Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Çağlayan GEREDELİ"'
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment
Externí odkaz:
https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzafer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/62814a4471cb45089f6723c0cccc8157
Autor:
Muhammed Mustafa Atcı, Çağlayan Geredeli, Seval Ay, Abdullah Sakin, Biray Ertürk, Şaban Seçmeler, Serdar Arıcı, Ruhper Çekin, Nurgül Yaşar, Orçun Can, Şener Cihan, Mahmut Gümüş
Publikováno v:
European Journal of Breast Health, Vol 17, Iss 2, Pp 123-127 (2021)
Objective:This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) .Materials and Methods:This stud
Externí odkaz:
https://doaj.org/article/8acb16f0797b415286c35d3e43a5b7c2
Publikováno v:
Rare Tumors, Vol 5, Iss 3, Pp e41-e41 (2013)
Malignant mesothelioma is a disease that originates from mesenchymal cells. It is related to the occupational or environmental exposure to asbestos. The treatment remains controversial because it is commonly diagnosed at a very late stage, and the pr
Externí odkaz:
https://doaj.org/article/c39938a95bb546d7aa255590c2e58705
Autor:
Muzaffer Uğraklı, Mehmet Zahid Koçak, Gülhan Dinç, Tuğrul Burak Genç, Melek Çağlayan, Selin Uğraklı, Engin Hendem, Muhammed Muhiddin Er, Dilek Çağlayan, Melek Karakurt Eryılmaz, Murat Araz, Çağlayan Geredeli, Ali Murat Tatlı, Orhan Önder Eren, Mehmet Artaç
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a788039bc355af311efa8104b1f089
https://doi.org/10.1007/s00432-023-04844-6
https://doi.org/10.1007/s00432-023-04844-6
Autor:
Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, Ali Murat Tatlı, Sema Sezgin Göksu, Melek Karakurt Eryılmaz, Murat Araz, Mehmet Artaç
Publikováno v:
European journal of clinical pharmacology.
Aim To evaluate the difference of progression free survival between the patients using concomitant proton pump inhibitors and non-users in the patients using CDK 4/6 inhibitors with HR + and HER2 negative mBC. Methods We included 86 patients with HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd74c798c1377980ddcaf43d9be60a1f
https://pubmed.ncbi.nlm.nih.gov/36520173
https://pubmed.ncbi.nlm.nih.gov/36520173
Autor:
Ayse Irem Yasin, Sabin Göktas Aydin, Bilge Sümbül, Lokman Koral, Melih Şimşek, Çağlayan Geredeli, Akın Öztürk, Perihan Perkin, Derya Demirtaş, Engin Erdemoglu, İlhan Hacıbekiroglu, Emre Çakır, Eda Tanrıkulu, Ezgi Çoban, Melike Ozcelik, Sinemis Çelik, Fatih Teker, Asude Aksoy, Sedat T Fırat, Ömer Tekin, Ziya Kalkan, Orhan Türken, Bala B Oven, Faysal Dane, Ahmet Bilici, Abdurrahman Isıkdogan, Mesut Seker, Hacı M Türk, Mahmut Gümüş
Publikováno v:
Future Oncology
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce80e141c2165fb933786d2089960e2a
https://hdl.handle.net/11424/286170
https://hdl.handle.net/11424/286170
Autor:
Muhammed Mustafa ATCI, Orçun CAN, Şaban SEÇMELER, Abdullah SAKİN, Seval AY, Şener CİHAN, Oğuzhan SELVİ, Çağlayan GEREDELİ
ABS TRACT Objective: Our study aimed to analyze imatinib’s efficacy, tolerability, and safety in treating naive patients with unresectable and progressive desmoid tumors. Material and Methods: The data of patients who were ≥18 years old diagnosed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b0372752795cf36f1a4cea3b0f0dd0
https://hdl.handle.net/20.500.12713/3254
https://hdl.handle.net/20.500.12713/3254
Autor:
Çağlayan Geredeli
Publikováno v:
Ortadoğu Tıp Dergisi. 11:10-14
Amac : Mikrotubul inhibitoru olan eribulin mesilat antrasiklin ve taksana rezistant metastatik meme kanserli hastalarda kullanimi kabul edilmistir. Amac eribulin mesilatin etkinligini arastirmak. Gerec ve Yontemler: Retrospektif calismada Istanbul Ok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b001e4724c4c6cd6200479287d30855e
https://doi.org/10.21601/ortadogutipdergisi.409706
https://doi.org/10.21601/ortadogutipdergisi.409706
Autor:
Filiz Özülker, Çağlayan Geredeli, Sevda Sağlampınar Karyağar, Serdar Arici, Oğuzhan Selvi, Savaş Karyağar, Osman Güven
Publikováno v:
Nuclear medicine communications. 42(9)
Objective In patients with metastatic castration-resistant prostate cancer (mCRPCa), enzalutamide is administered when docetaxel treatment fails. The purpose of the study was to evaluate the relationship between prostate-specific antigen (PSA) respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756814d8482a6f5d970e032ea08b4dbb
https://pubmed.ncbi.nlm.nih.gov/33958536
https://pubmed.ncbi.nlm.nih.gov/33958536